Immunotherapy in Multiple Myeloma.
To review the use of monoclonal antibodies (mAbs) in the treatment of multiple myeloma (MM) and the management of most common side effects. Review of journal articles related to mAbs in MM. The therapeutic options for MM have improved dramatically and the development of mAbs has been associated with improvement in clinical outcomes and favorable toxicity profiles. With appropriate pre-medications and nursing management, mAbs are a well-tolerated treatment option for myeloma patients.